TOKYO, 23 March 2018 – intellim Corporation and Clinical Research Malaysia (CRM) have signed a Memorandum of Understanding (MoU) to establish a new strategic partnership between both companies in clinical research. The inking of this MoU spells out support on clinical research activities in both Malaysia and Japan, as well as in business development and networking opportunities for both organizations.
This new partnership will have the potential to expand pharmaceutical and medical device development especially with regards to new drugs in Malaysia from the Japanese companies. With the incoming of these trials, Malaysian patients may benefit from potentially better treatment options and standard of care. Malaysia has existing experience, facilities, processes, regulations and manpower in conducting clinical trials for over 20 years. With the current Malaysian Economic Transformation Program (ETP) that targets clinical research as one of its main drivers in economic growth, Malaysia has accelerated its efforts to reach out to foreign players in the clinical research field through CRM.
intellim Corporation is the fastest-growing independent contract research organization in Japan that provides full fledge services for clinical development ranging from research and development to the various stages of clinical trial. intellim’s vast global experience in drug development and expertise particularly in the field of oncology makes it the ideal partner to collaborate with in view of the growing pipeline of oncology drugs in clinical trials.
The cooperation between both parties may result in an inflow of more clinical trials into Malaysia in the next few years. With the Ministry of Health’s backing and an innate understanding of the local clinical research landscape, CRM will be able to support intellim Corporation’s clinical trial needs with its complementary feasibility services, clinical trial management, as well as in other areas including intellim’s establishment in Malaysia.
The MoU is signed between CEO of CRM, Dr. Akhmal Yusof and President and CEO of intellim Corporation, Mr. Masakuni Ukita, and witnessed by the Ambassador of Malaysia to Japan, His Excellency Dato’ Ahmad Izlan Idris.
Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to- end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities.
About intellim Corporation
intellim Corporation is a contract research organization (CRO) established in Japan in 2005. As a full-serviced CRO, intellim provides all clinical development services encompassing regulatory affairs strategic consulting, clinical development of phase I–III and post approval clinical studies, as well as submission for marketing approval support. intellim has experience in conducting a wide variety of projects with both Japanese and global pharmaceutical companies, including almost all of the international “Big Pharma”. They have a wealth of experience conducting studies in Japan as well as across several countries in Asia and are well versed in many therapeutic regions, specializing in oncology, regenerative medicine, and rare diseases.